This global educational program is intended for hematologists, medical oncologists, and other healthcare professionals who treat patients with MDS and AML.
The goal of this activity is to improve the knowledge and competence in the rationale for and use of CD47 targeting agents in the treatment of MDS and AML.
Upon completion of this activity, participants should be able to:
Communicate to colleagues and patients the role of CD47 in evasion of an immune response to higher-risk MDS and AML and the mechanism of action of anti-CD47 agents
Differentiate the efficacy and safety profile of anti-CD47 agents from other classes of agents used to treat MDS and AML
Select patients who meet the inclusion criteria for enrollment on pivotal trials of anti-CD47 agents in MDS and AML
Plan treatment strategies for patients with MDS and AML that include anti-CD47 agents when they become available
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Michael Heuser, MD
Chair for Molecular Therapies in Hematology
Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation
Hannover Medical School
Michael Heuser, MD: consultant/advisor/speaker: AbbVie, Amgen, Bristol Myers Squibb, Certara, Glycostem, Jazz, Janssen, LabDelbert, Novartis, Pfizer, PinotBio, Servier, Sobi; researcher: AbbVie, Agios, Astellas, BerGenBio, Bristol Myers Squibb, Glycostem, Jazz, Karyopharm, Loxo Oncology, PinotBio.
Naval G. Daver, MD
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Naval G. Daver, MD: consultant/advisor: AbbVie, Agios, Amgen, Arog, Astellas, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Genentech, Gilead, Immunogen, Jazz, Kite, Novartis, Pfizer, Servier, Shattuck Labs, Stemline/Menarini, Syndax, Trillium; researcher: AbbVie, Amgen, Astellas, Bristol Myers Squibb, Daiichi Sankyo, Fate, Genentech, Gilead, Glycomimetics, Hanmi, Immunogen, Kite, Novoimmune, Pfizer, Servier, Trillium, Trovagene.
Amer Zeidan, MBBS, MPH
Associate Professor, Internal Medicine
Leader, Leukemia and Myeloid Disease Aligned Research Team (DART)
Director, Hematology Early Therapeutics Research
Yale Cancer Center and Smilow Cancer Hospital
Yale University School of Medicine
New Haven, Connecticut
Amer Zeidan, MBBS, MPH: researcher: AbbVie, ADC Therapeutics, Amgen, Aprea, Astex, Boehringer Ingelheim, Cardiff Oncology, Celgene/Bristol Myers Squibb, Incyte, Medimmune/AstraZeneca, Novartis, Otsuka, Pfizer, Takeda, Trovagene; consultant: Acceleron, Agios, Amgen, Aprea, Astellas, Astex, BeyondSpring, Boehringer Ingelheim, Cardiff Oncology, Cardinal Health, Celgene/Bristol Myers Squibb, Daiichi Sankyo, Epizyme, Gilead Sciences, Incyte, Ionis, Janssen, Jazz, Kura, Novartis, Otsuka, Pfizer, Seattle Genetics, Syndax, Taiho, Takeda, Trovagene, Tyme.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from August 15, 2023, through August 14, 2024:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
The program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.